Partnerships Rutgers University: license agreement for LNC technology
Indications
Cryptococcal meningitis(Phase 2)
Invasive aspergillosis (patients with limited treatment options)(Phase 3)
Status note EnACT Phase 2 in cryptococcal meningitis completed; positioned for single Phase 3 registration trial (ORALTO) for invasive aspergillosis in patients with limited treatment options. Clinical development paused following Oct 2024 workforce reduction (80%); pursuing licensing, sale or other transaction; R&D expense $0 in H1 2026. Jul 2026 agreements contemplated selling Nanotechnologies (owner of MAT2203) and combining with GH Power; closing not assured.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.